Monday, 12 December 2011

KPA KPA KPA THREE CLAPS FOR GSK

I just got this news and thought it was nice to share it with everyone ,please let your people know as this is a step forward in the right direction. Now  we can say some stake holders are thinking . We all know  how difficult and expensive some of these hospitals and health care providers make these vaccines.

PRESS RELEASE
  GSK & ACPN Bring Vaccines Access Points to 81 Retail Outlets in Nigeria
            through the ‘Neighbourhood Vaccine Access Project’.
(Embedded image moved to file: pic06483.jpg)

Lagos,  Nigeria,  December  08,  2011:  GlaxoSmithKline,  (GSK), one of the
world’s  leading  pharmaceutical and healthcare companies, has joined hands
with  the  Association  of  Community  Pharmacists  of  Nigeria, (ACPN), to
initiate  a scheme called Neighbourhood Vaccine that creates easy access to
affordable vaccines.

Under the partnership, vaccines for prevention of diseases such as cervical
cancer,  Chicken Pox, Hepatitis B, Typhoid fever, Meningitis, Measles mumps
and  Rubella,  and  Hepatitis A, will be available at several neighbourhood
pharmacies  and  clinics across the country thereby making the drugs easier
to be purchased.

The  Managing  Director,  GlaxoSmithKline  Pharmaceutical,  Anglophone West
Africa,  Mr  Lekan  Asuni,  said,  the  Neighbourhood  Vaccine Access Point
project  is a further proof of the commitment of his firm towards improving
the  quality  of  human life by facilitating a quicker access to drugs in a
manner better than what has been available.

‘GSK  has always sought for ways and means of improving the quality of life
of  people and through this scheme by presenting the opportunity for people
to  have  first  and  fast  access  to  high  quality healthcare. Community
Pharmacy  practice  is  a key success factor and essential component in the
health  of the nation, so deepening their skill base, in our view is a very
worthy investment,’ Asuni said.

According  to  him,  it  is better to prevent diseases rather than allowing
people  to  contract  them  which  then leads to unnecessary sufferings and
attendant  high  costs of caring for preventable-diseases, or suffering the
economic  consequences  of  lost  work  time  and  productivity.  In  all,
accredited  pharmacy  stores  are  to serve as micro distribution points of
these  vaccines  to  unreached  clinics in the first phase of the programme
that  has  already  been rolled out. The access points/pharmacies will also
serve  as  centres  for  obtaining  information  on  vaccines  preventable
diseases.

In  another  interview,  National  Chairman,  ACPN,  Dr  Ejiro Foyibo, said
vaccines prevent the spread of diseases to vulnerable people who are not or
cannot  be  vaccinated and also beneficial for employers as they contribute
to work productivity and lower costs of health care.

Foyibo  added  that ACPN in association with GlaxoSmithKline will enlighten
the  public  effectively  so  that  people can identify with the accredited
neighbourhood access points/pharmacies and clinics closest to them all over
the country, involved in this programme.

According  to  her,  immunisation programmes have a long history of success
and  in  order  to  ensure that this scheme is also successful, information
will be provided in national dailies on locations of accredited pharmacies.

ENDS



GSK Biologicals
GlaxoSmithKline  Biologicals  (GSK Biologicals), GlaxoSmithKline’s vaccines
business,  is  one of the world’s leading vaccine companies and a leader in
innovation.  The  company  is  active  in vaccine research, development and
production  with  over  30  vaccines  approved for marketing and 20 more in
development  –  both  in  the  prophylactic  and  therapeutic  fields.
Headquartered  in  Belgium,  GSK  Biologicals  has  14  manufacturing sites
strategically  positioned  around  the  globe.  In  2010,  GSK  Biologicals
distributed  1.43  billion  doses  of vaccines to 179 countries in both the
developed and the developing world.

Through  its  accomplished and dedicated workforce, GSK Biologicals applies
its  expertise  to  the discovery of innovative vaccines that contribute to
the health and well-being of people of all generations around the world.

GlaxoSmithKline  – one of the world’s leading research-based pharmaceutical
and  healthcare  companies – is committed to improving the quality of human
life  by  enabling  people  to  do  more, feel better and live longer.  For
further information, please visit www.gsk.com
 
please lets pass the word around , it means 2 things, AVAILABLE AND AFFORDABLE.